Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Total Liabilities (2020 - 2025)

Mainz Biomed's Total Liabilities history spans 5 years, with the latest figure at $7.2 million for Q4 2024.

  • For Q4 2024, Total Liabilities fell 40.86% year-over-year to $7.2 million; the TTM value through Dec 2024 reached $7.2 million, down 40.86%, while the annual FY2024 figure was $7.2 million, 40.86% down from the prior year.
  • Total Liabilities for Q4 2024 was $7.2 million at Mainz Biomed, down from $12.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $12.2 million in Q4 2023 and bottomed at $3.4 million in Q4 2020.
  • The 5-year median for Total Liabilities is $6.1 million (2022), against an average of $6.5 million.
  • The largest annual shift saw Total Liabilities surged 97.88% in 2023 before it plummeted 40.86% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $3.4 million in 2020, then grew by 7.75% to $3.7 million in 2021, then soared by 67.0% to $6.1 million in 2022, then skyrocketed by 97.88% to $12.2 million in 2023, then tumbled by 40.86% to $7.2 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Total Liabilities are $7.2 million (Q4 2024), $12.2 million (Q4 2023), and $6.1 million (Q4 2022).